ChiCTR2500108758 版本V1.0 版本创建时间2025/09/04 16:01:48 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500108758 

最近更新日期:

Date of Last Refreshed on:

2025-09-04 16:01:12 

注册时间:

Date of Registration:

2025-09-04 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

肝癌合并肝硬化患者围术期凝血功能的回顾性分析

Public title:

Retrospective analysis of perioperative coagulation function in patients with hepatocellular carcinoma complicated by cirrhosis

注册题目简写:

English Acronym:

研究课题的正式科学名称:

肝癌合并肝硬化患者围术期凝血功能的回顾性分析

Scientific title:

Retrospective analysis of perioperative coagulation function in patients with hepatocellular carcinoma complicated by cirrhosis

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

马渝珠 

研究负责人:

程波 

Applicant:

Yuzhu Ma 

Study leader:

Bo Cheng 

申请注册联系人电话:

Applicant telephone:

+86 132 7197 3375

研究负责人电话:

Study leader's
telephone:

+86 139 8376 0123

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

mayuzhu200@163.com

研究负责人电子邮件:

Study leader's E-mail:

7300703@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

重庆市渝中区友谊路1号

研究负责人通讯地址:

重庆市渝中区友谊路1号

Applicant address:

No. 1 Youyi Road, Yuzhong District, Chongqing

Study leader's address:

No. 1 Youyi Road, Yuzhong District, Chongqing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

重庆医科大学附属第一医院

Applicant's institution:

The First Affiliated Hospital of Chongqing Medical University

研究负责人所在单位:

重庆医科大学附属第一医院

Affiliation of the Leader:

The First Affiliated Hospital of Chongqing Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2024年科研伦审(2024-212-01)

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

重庆医科大学附属第一医院伦理委员会

Name of the ethic committee:

Medical Research Ethics Review Committee of the First Affiliated Hospital of Chongqing Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2024-09-23 00:00:00

伦理委员会联系人:

严青

Contact Name of the ethic committee:

Qing Yan

伦理委员会联系地址:

重庆医科大学附属第一医院

Contact Address of the ethic committee:

No. 1 Youyi Road, Yuzhong District, Chongqing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 23 8901 1876

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

重庆医科大学附属第一医院

Primary sponsor:

The First Affiliated Hospital of Chongqing Medical University

研究实施负责(组长)单位地址:

重庆市渝中区友谊路1号

Primary sponsor's address:

No. 1 Youyi Road, Yuzhong District, Chongqing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

重庆

市(区县):

Country:

China

Province:

Chongqing

City:

单位(医院):

重庆医科大学附属第一医院

具体地址:

重庆市渝中区友谊路1号

Institution
hospital:

The First Affiliated Hospital of Chongqing Medical University

Address:

No. 1 Youyi Road, Yuzhong District, Chongqing

经费或物资来源:

重庆医科大学附属第一医院科研项目经费

Source(s) of funding:

Scientific research project funds by The First Affiliated Hospital of Chongqing Medical University

研究疾病:

肝脏  

Target disease:

liver

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

病例研究 

Study design:

Case study 

研究目的:

本研究通过回顾性分析探讨合并肝硬化的肝细胞癌患者的围术期凝血状态,为围术期肝病患者凝血功能调控和管理提供科学依据。  

Objectives of Study:

This study explores the perioperative coagulation status of patients undergoing liver surgery through a retrospective analysis, providing a scientific basis for the regulation and management of coagulation function in perioperative liver disease patients.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

2023 年肝细胞肝癌合并肝硬化患者

Inclusion criteria

2023 Patients with Hepatocellular Carcinoma Combined with Cirrhosis

排除标准:

Exclusion criteria:

None

研究实施时间:

Study execute time:

From 2024-12-01 00:00:00 To 2025-10-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-01-01 00:00:00 To 2025-09-24 00:00:00

干预措施:

Interventions:

组别:

肝细胞肝癌合并肝硬化

样本量:

200

Group:

Hepatocellular carcinoma combined with cirrhosis

Sample size:

干预措施:

干预措施代码:

Intervention:

No

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

重庆 

市(区县):

 

Country:

China

Province:

Chongqing

City:

单位(医院):

重庆医科大学附属第一医院  

单位级别:

三甲 

Institution
hospital:

The First Affiliated Hospital of Chongqing Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

血栓弹力图

指标类型:

主要指标

Outcome:

Thromboelastogram

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

国际标准化比值

指标类型:

次要指标

Outcome:

International normalized ratio?

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

研究公开发表后半年,邮件联系研究负责人合理获取。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Six months after the publication of the research, contact the research leader via email to obtain reasonable information.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

Excel表格及SPSS软件

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Excel tables and SPSS software

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-09-04 16:01:12